Biopharma AI
By
Merck’s First Fully AI-Designed Oncology Drug: 2027 China Approval Nears or Hype Peaks?
Merck’s January 26–March 2026 trajectory signals China will approve its first fully AI-designed compound by 2027—the world’s first…
DeepSeek AI Hits Hundreds of Hospitals: Pathology Revolution or Urban Elite Tool?
DeepSeek chatbot expanded to hundreds of hospitals across Shanghai, Shenzhen, and Chengdu on March 2, 2026—processing 3,000 pathology…
China’s $2-3B AI Healthcare Pilots Launch: Rural Revolution or Data Control Play?
China’s National Health Commission launched pilots March 1-3, 2026, under its CNY 15-20B ($2-3B) AI strategy—rolling out AI…
NVIDIA Survey: 70% US Healthcare AI Adoption—Efficiency Lifeline or Insider Breach Timebomb?
NVIDIA’s March 1 survey shows 70% of US healthcare organizations now use AI, mainly to save time on…
Can Edison Scientific and Population Health Partners’ AI Build the Next $10 Billion Biotech?
Key Highlights The Deal at a Glance Announced on June 29, 2026, the partnership pairs PHP’s proven track…
Can a $2.5 Billion AI Alliance Between Insilico Medicine and SK Biopharmaceuticals Rewrite the Future of Neuroimmune Drug Discovery?
Key Highlights The Deal at a Glance Announced at the BIO 2026 International Convention, the collaboration grants Insilico…
